Abstract:Abstract Hepatocellular carcinoma (HCC) is the fourth most common cause of cancer fatalities worldwide, with chronic hepatitis B infection accounting for 60% of cases. In the majority of new diagnoses, primary tumor size contraindicates surgical resection, limiting available treatment options to rarely-curative interventions that generally have severe side effects. Overall, advanced HCC is largely incurable, with a five year survival rate of <5%. To expand the treatment pipeline, we conducted a high-throughput screening campaign of our 85,000-compound small molecule library to identify agents that would exhibit selective cytotoxicity for HCC-derived cell lines, as compared to immortalized non-transformed human hepatocytes. A disubstituted aminothiazole, termed HBF-0079, emerged as a potent and selective inhibitor of cell growth and viability in the HCC lines Huh7, Hep3b, HepaRG, MHCC97H and MHCC97L, and the hepatoblastoma line HepG2, with EC50 values from 0.7 to 33 μM. Conversely, growth and viability in the non-tumorigenic hepatocyte lines THLE2 and PH5CH, and several other non-HCC cancer lines, showed only moderate to no sensitivity. Subsequent structure-activity relationship studies have identified relevant features of the molecule, and resulted in two compounds that retain selectivity and improve EC50 to < 0.1 μM in Huh7. In a murine xenograft model, growth of Hep3B-derived tumors was significantly delayed by either systemic or intratumoral administration of HBF-0079. As determined in cell culture withdrawal experiments, incubation of Huh7 cells with HBF-0079 resulted in irreversible onset of growth arrest and apoptosis. Cell cycle analysis indicated arrest in G1/G0, with subsequent entry of cells into a sub-G0 population consistent with apoptotic cell death. While a putative molecular target is currently being confirmed, we have determined that treated Huh7 cells undergo loss of AKT phosphorylation at the mTORC2-targeted residue S473, with subsequent loss of phosphorylation of the mTORC1 targets SK6 and 4EBP1; these observations are consistent with cell cycle arrest and onset of apoptosis, ostensibly through loss of AKT survival signaling and global translational shutoff. Conversely, phosphorylation of Akt or mTORC1 targets is not affected in the non-sensitive PH5CH line. Thus, we have identified a cytotoxic molecule with in vitro selectivity for liver-derived cancer cells. In vivo efficacy studies and chemical hit-to-lead optimization are currently ongoing. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2011 Nov 12-16; San Francisco, CA. Philadelphia (PA): AACR; Mol Cancer Ther 2011;10(11 Suppl):Abstract nr C68.

Combined Inhibition of AURKA and HSF1 Suppresses Proliferation and Promotes Apoptosis in Hepatocellular Carcinoma by Activating Endoplasmic Reticulum Stress

Targeting high Aurora kinases expression as an innovative therapy for hepatocellular carcinoma.

Synergistic suppression effect on tumor growth of hepatocellular carcinoma by combining oncolytic adenovirus carrying XAF1 with cisplatin

Cyclin-Dependent Kinase 9 Inhibition As a Potential Treatment for Hepatocellular Carcinoma

The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma.

Aurora-A promotes chemoresistance in hepatocelluar carcinoma by targeting NF-kappaB/microRNA-21/PTEN signaling pathway.

HIF-1 α RNAi Combined with Asparagus Polysaccharide Exerts an Antiangiogenesis Effect on Hepatocellular Carcinoma In Vitro and In Vivo

HGFK1 Enhances the Anti-Tumor Effects of Angiogenesis Inhibitors via Inhibition of CD90+ CSCs in Hepatocellular Carcinoma

Evaluation of the Antitumor Efficacy of Rnai-Mediated Inhibition of Cdc20 and Heparanase in an Orthotopic Liver Tumor Model

Aurora-a Confers Radioresistance in Human Hepatocellular Carcinoma by Activating NF-κB Signaling Pathway

The Role of Aurora A in Hypoxia-Inducible Factor 1Α-Promoting Malignant Phenotypes of Hepatocelluar Carcinoma

Antitumor Activity of the Combination of an Hsp90 Inhibitor and A Pi3k/Mtor Dual Inhibitor Against Cholangiocarcinoma

Dual Targeting Of Mtorc1/C2 Complexes Enhances Histone Deacetylase Inhibitor-Mediated Antitumor Efficacy In Primary Hcc Cancer In Vitro And In Vivo

Combined Anti-Tumor Effects of IFN-α and Sorafenib on Hepatocellular Carcinoma in Vitro and in Vivo

Suppression Of Akt Anti-Apoptotic Signaling By A Novel Drug Candidate Results In Growth Arrest And Apoptosis Of Hepatocellular Carcinoma Cells

Combination of HSP90 and Autophagy Inhibitors Promotes Hepatocellular Carcinoma Apoptosis Following Incomplete Thermal Ablation

Suppression of NSCLC progression via the co-administration of Danusertib, an AURK inhibitor, and KRIBB11, an HSF1 inhibitor

Effect of simultaneous silencing of both epidermal growth factors receptors and insulin-like growth factors-1 receptors by small interfering RNA on cycle and apoptosis of hepatocellular carcinoma cells

Abstract C68: Suppression of AKT/mTOR Antiapoptotic Signaling by a Novel Drug Candidate Results in Growth Arrest and Apoptosis of Hepatocellular Carcinoma-Derived Cell Lines.

Dual Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Inhibition Elicits Antitumor Immunity and Enhances Programmed Cell Death-1 Checkpoint Blockade in Hepatocellular Carcinoma

Hypoxia-inducible enhancer/α-fetoprotein promoter-driven RNA interference targeting STK15 suppresses proliferation and induces apoptosis in human hepatocellular carcinoma cells